Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (Molecular Autism, (2021), 12, 1, (38), 10.1186/s13229-021-00447-5)

Andrew W. Zimmerman, Kanwaljit Singh, Susan L. Connors, Hua Liu, Anita A. Panjwani, Li‑Ching ‑C Lee, Eileen Diggins, Ann Foley, Stepan Melnyk, Indrapal N. Singh, S. Jill James, Richard E. Frye, Jed W. Fahey

Research output: Contribution to journalComment/debatepeer-review

Abstract

Following publication of the original article [1], the authors pointed out that the part of the text in Methods part was incorrectly stipulated and should read as follows: We were unable to produce or obtain SF-rich preparations for this study like those used in our previous study [6]. Based on prior testing of alternative preparations [25–27], we used commercially available crushable tablets containing broccoli seed and sprout extracts as a source of GR (equivalent to 34 μmol GR calculated to yield at least ~ 15 μmol SF) and active myrosinase enzyme. Tablets commercially produced as Avmacol® were provided by Nutramax Laboratories, Inc., Edgewood, MD. Placebo tablets, identical in size and similar in appearance to the active tablets, contained microcrystalline cellulose, red, yellow and black coloring and magnesium stearate, and were produced by Dr. Stephen Hoag, University of Maryland Department of Pharmacy.

Original languageEnglish (US)
Article number44
JournalMolecular Autism
Volume12
Issue number1
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Molecular Biology
  • Developmental Neuroscience
  • Developmental Biology
  • Psychiatry and Mental health

Fingerprint

Dive into the research topics of 'Correction to: Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder (Molecular Autism, (2021), 12, 1, (38), 10.1186/s13229-021-00447-5)'. Together they form a unique fingerprint.

Cite this